Eli Lilly, Zepbound and Outperforms Wegovy
Digest more
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult diseases.
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.
Explore more
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.
Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...
The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.
4don MSN
The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the two sides said.
Gov. Mike Braun visited Lebanon Tuesday to help break ground for the $4.5 billion Eli Lilly Medicine Foundry in Lebanon. The foundry is the first research and development site of its kind in the world and will combine research,